+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
Filgrastim & Biosimilars Market - Global Forecast 2025-2030- Product Image
Filgrastim & Biosimilars Market - Global Forecast 2025-2030- Product Image
Sale

Filgrastim & Biosimilars Market - Global Forecast 2025-2030

  • PDF Icon

    Report

  • 190 Pages
  • August 2025
  • Region: Global
  • 360iResearch™
  • ID: 6136953
UP TO OFF until Jan 01st 2026
1h Free Analyst Time
Description Jump to:
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.

The Filgrastim market is undergoing rapid transformation as biosimilar products disrupt established dynamics, creating new opportunities and strategic challenges. Evolving regulations, emerging technologies, and global tariff policies demand a proactive approach from industry leaders to maintain competitiveness and capture value.

Market Snapshot: Filgrastim and Biosimilars

The Filgrastim market, integral to managing neutropenia across oncology and hematology, is expanding driven by technological innovation, biosimilar adoption, and the expiration of key patents. The market is shaped by increased patient access, evolving payer strategies, and a new wave of entrants leveraging real-world evidence and cost-efficient manufacturing. This changing environment is marked by growing collaborations, updated reimbursement models, and diversification of delivery methods, signaling a pivotal phase of industry realignment and regional variation.

Scope & Segmentation

This report provides a comprehensive assessment of the Filgrastim landscape, encompassing product types, application areas, user settings, distribution, dosage forms, and market reach across diverse geographies and companies. Key areas evaluated include:

  • Product Type: Biosimilar Filgrastim (Accofil, Nivestim, Zarxio) and Originator Filgrastim.
  • Application: Chemotherapy-induced neutropenia (hematologic malignancy, solid tumor), severe chronic neutropenia, and stem cell mobilization.
  • End User: Homecare, hospital, and specialty clinic settings.
  • Distribution Channel: Hospital pharmacy, online pharmacy, and retail pharmacy options supporting varying care modalities.
  • Dosage Form: Prefilled syringe and vial presentations adapted to user preference and logistical needs.
  • Strength: 300 microgram and 480 microgram strengths meeting individualized patient requirements.
  • Geographic Coverage: Americas (United States, Canada, Mexico, Brazil, Argentina), Europe, Middle East & Africa (including United Kingdom, Germany, France, and other leading countries), and Asia-Pacific (China, India, Japan, Australia, South Korea, and more).
  • Leading Companies: Amgen Inc., Sandoz International GmbH, Teva Pharmaceutical Industries Ltd., Pfizer Inc., Viatris Inc., Biocon Biologics Ltd., Celltrion Inc., Apotex Inc., Intas Pharmaceuticals Ltd., Fresenius Kabi AG.

Key Takeaways

  • Biosimilar Filgrastim is reshaping competitive dynamics, with more companies entering as major patents lapse and regulatory agencies streamline biosimilar approval pathways.
  • Innovation in cell culture, purification, and analytics has improved product consistency while expediting commercialization, benefiting both access and quality benchmarks.
  • Strategic alliances, value-based contracting, and enhanced patient support offerings have become central to stakeholder engagement in this evolving field.
  • Homecare settings are gaining traction, backed by training tools and digital health platforms, while hospitals and specialty clinics still play key roles in administration and procurement.
  • Regional market differences are significant: North America leads in biosimilar uptake with supportive policy, Western Europe benefits from centralized procurement, and Asia-Pacific is accelerating adoption via government incentives and broader hospital formularies.
  • Product differentiation is being advanced through prefilled syringes, tailored formulations, and digital tools that support adherence and track outcomes.

Tariff Impact on Filgrastim and Biosimilar Dynamics

Recent and anticipated U.S. tariff reforms are altering the import landscape for Filgrastim and its biosimilar products. Manufacturers are revisiting supply chain structure, with strategic movement toward regional sourcing, local partnerships, and contract manufacturing to mitigate risks from changing import duties and supply chain volatility. Hospitals, distributors, and specialty pharmacies are recalibrating agreements in response to evolving duty structures, influencing pricing strategies and market entry. Vertically integrated companies with localized production may gain resilience in the face of global trade changes.

Methodology & Data Sources

This report utilizes a multi-pronged methodology, combining secondary research from clinical literature, regulatory databases, and patent filings with primary insights from industry interviews, surveys, and expert panels. Analytical rigor ensures data validation through quantitative triangulation and peer review.

Why This Report Matters

  • Offers strategic direction for optimizing product development, commercialization, and stakeholder engagement.
  • Enables informed decision-making by illuminating critical technological, regulatory, and regional trends.
  • Provides clear segmentation and actionable insights for resource allocation and go-to-market strategies.

Filgrastim Market: Primary Keyword in Focus

Filgrastim and its biosimilars represent a rapidly evolving therapeutic area, where innovation, efficiency, and partnerships define sustainable market leadership. Senior decision-makers benefit from understanding intricate clinical applications, supply chain models, and new tariff environments shaping the future of supportive oncology and hematology care.

Conclusion

As biosimilar adoption continues to accelerate, the Filgrastim market presents both unique challenges and promising growth avenues. Strategic foresight and agility will be essential to realize sustained success in this reshaped landscape.



This product will be delivered within 1-3 business days.

Table of Contents

1. Preface
1.1. Objectives of the Study
1.2. Market Segmentation & Coverage
1.3. Years Considered for the Study
1.4. Currency & Pricing
1.5. Language
1.6. Stakeholders
2. Research Methodology
2.1. Define: Research Objective
2.2. Determine: Research Design
2.3. Prepare: Research Instrument
2.4. Collect: Data Source
2.5. Analyze: Data Interpretation
2.6. Formulate: Data Verification
2.7. Publish: Research Report
2.8. Repeat: Report Update
3. Executive Summary
4. Market Overview
4.1. Introduction
4.2. Market Sizing & Forecasting
5. Market Dynamics
5.1. Emergence of next-generation long-acting filgrastim biosimilars with improved patient adherence profiles
5.2. Impact of patent expirations on accelerated uptake of filgrastim biosimilars in European oncology protocols
5.3. Influence of real-world evidence studies on payer reimbursement policies for filgrastim biosimilars
5.4. Regulatory harmonization efforts to expedite approval of interchangeable filgrastim biosimilars across global markets
5.5. Strategic partnerships between originator biologic firms and biosimilar developers to expand access in emerging economies
5.6. Integration of pharmacoeconomic modeling in formulary decision-making for long-acting pegfilgrastim biosimilars among US health systems
5.7. Price erosion dynamics and competitive pricing strategies in the US filgrastim biosimilar market post-2020 entry
5.8. Manufacturer-led patient support programs and their role in boosting adherence to filgrastim biosimilar therapies
5.9. Adoption of digital adherence monitoring tools in long-acting filgrastim treatment regimens to reduce neutropenia hospitalizations
5.10. Supply chain resilience measures implemented to mitigate biologic shortages during global disruptions
6. Market Insights
6.1. Porter’s Five Forces Analysis
6.2. PESTLE Analysis
7. Cumulative Impact of United States Tariffs 2025
8. Filgrastim & Biosimilars Market, by Product Type
8.1. Introduction
8.2. Biosimilar Filgrastim
8.2.1. Accofil
8.2.2. Nivestim
8.2.3. Zarxio
8.3. Originator Filgrastim
9. Filgrastim & Biosimilars Market, by Application
9.1. Introduction
9.2. Chemotherapy Induced Neutropenia
9.2.1. Hematologic Malignancy Treatment
9.2.2. Solid Tumor Treatment
9.3. Severe Chronic Neutropenia
9.4. Stem Cell Mobilization
10. Filgrastim & Biosimilars Market, by End User
10.1. Introduction
10.2. Homecare
10.3. Hospital
10.4. Specialty Clinic
11. Filgrastim & Biosimilars Market, by Distribution Channel
11.1. Introduction
11.2. Hospital Pharmacy
11.3. Online Pharmacy
11.4. Retail Pharmacy
12. Filgrastim & Biosimilars Market, by Dosage Form
12.1. Introduction
12.2. Prefilled Syringe
12.3. Vial
13. Filgrastim & Biosimilars Market, by Strength
13.1. Introduction
13.2. 300 Microgram
13.3. 480 Microgram
14. Americas Filgrastim & Biosimilars Market
14.1. Introduction
14.2. United States
14.3. Canada
14.4. Mexico
14.5. Brazil
14.6. Argentina
15. Europe, Middle East & Africa Filgrastim & Biosimilars Market
15.1. Introduction
15.2. United Kingdom
15.3. Germany
15.4. France
15.5. Russia
15.6. Italy
15.7. Spain
15.8. United Arab Emirates
15.9. Saudi Arabia
15.10. South Africa
15.11. Denmark
15.12. Netherlands
15.13. Qatar
15.14. Finland
15.15. Sweden
15.16. Nigeria
15.17. Egypt
15.18. Turkey
15.19. Israel
15.20. Norway
15.21. Poland
15.22. Switzerland
16. Asia-Pacific Filgrastim & Biosimilars Market
16.1. Introduction
16.2. China
16.3. India
16.4. Japan
16.5. Australia
16.6. South Korea
16.7. Indonesia
16.8. Thailand
16.9. Philippines
16.10. Malaysia
16.11. Singapore
16.12. Vietnam
16.13. Taiwan
17. Competitive Landscape
17.1. Market Share Analysis, 2024
17.2. FPNV Positioning Matrix, 2024
17.3. Competitive Analysis
17.3.1. Amgen Inc.
17.3.2. Sandoz International GmbH
17.3.3. Teva Pharmaceutical Industries Ltd.
17.3.4. Pfizer Inc.
17.3.5. Viatris Inc.
17.3.6. Biocon Biologics Ltd.
17.3.7. Celltrion Inc.
17.3.8. Apotex Inc.
17.3.9. Intas Pharmaceuticals Ltd.
17.3.10. Fresenius Kabi AG
18. ResearchAI
19. ResearchStatistics
20. ResearchContacts
21. ResearchArticles
22. Appendix
List of Figures
FIGURE 1. FILGRASTIM & BIOSIMILARS MARKET RESEARCH PROCESS
FIGURE 2. GLOBAL FILGRASTIM & BIOSIMILARS MARKET SIZE, 2018-2030 (USD MILLION)
FIGURE 3. GLOBAL FILGRASTIM & BIOSIMILARS MARKET SIZE, BY REGION, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 4. GLOBAL FILGRASTIM & BIOSIMILARS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 5. GLOBAL FILGRASTIM & BIOSIMILARS MARKET SIZE, BY PRODUCT TYPE, 2024 VS 2030 (%)
FIGURE 6. GLOBAL FILGRASTIM & BIOSIMILARS MARKET SIZE, BY PRODUCT TYPE, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 7. GLOBAL FILGRASTIM & BIOSIMILARS MARKET SIZE, BY APPLICATION, 2024 VS 2030 (%)
FIGURE 8. GLOBAL FILGRASTIM & BIOSIMILARS MARKET SIZE, BY APPLICATION, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 9. GLOBAL FILGRASTIM & BIOSIMILARS MARKET SIZE, BY END USER, 2024 VS 2030 (%)
FIGURE 10. GLOBAL FILGRASTIM & BIOSIMILARS MARKET SIZE, BY END USER, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 11. GLOBAL FILGRASTIM & BIOSIMILARS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024 VS 2030 (%)
FIGURE 12. GLOBAL FILGRASTIM & BIOSIMILARS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 13. GLOBAL FILGRASTIM & BIOSIMILARS MARKET SIZE, BY DOSAGE FORM, 2024 VS 2030 (%)
FIGURE 14. GLOBAL FILGRASTIM & BIOSIMILARS MARKET SIZE, BY DOSAGE FORM, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 15. GLOBAL FILGRASTIM & BIOSIMILARS MARKET SIZE, BY STRENGTH, 2024 VS 2030 (%)
FIGURE 16. GLOBAL FILGRASTIM & BIOSIMILARS MARKET SIZE, BY STRENGTH, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 17. AMERICAS FILGRASTIM & BIOSIMILARS MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 18. AMERICAS FILGRASTIM & BIOSIMILARS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 19. UNITED STATES FILGRASTIM & BIOSIMILARS MARKET SIZE, BY STATE, 2024 VS 2030 (%)
FIGURE 20. UNITED STATES FILGRASTIM & BIOSIMILARS MARKET SIZE, BY STATE, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 21. EUROPE, MIDDLE EAST & AFRICA FILGRASTIM & BIOSIMILARS MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 22. EUROPE, MIDDLE EAST & AFRICA FILGRASTIM & BIOSIMILARS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 23. ASIA-PACIFIC FILGRASTIM & BIOSIMILARS MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 24. ASIA-PACIFIC FILGRASTIM & BIOSIMILARS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 25. FILGRASTIM & BIOSIMILARS MARKET SHARE, BY KEY PLAYER, 2024
FIGURE 26. FILGRASTIM & BIOSIMILARS MARKET, FPNV POSITIONING MATRIX, 2024
FIGURE 27. FILGRASTIM & BIOSIMILARS MARKET: RESEARCHAI
FIGURE 28. FILGRASTIM & BIOSIMILARS MARKET: RESEARCHSTATISTICS
FIGURE 29. FILGRASTIM & BIOSIMILARS MARKET: RESEARCHCONTACTS
FIGURE 30. FILGRASTIM & BIOSIMILARS MARKET: RESEARCHARTICLES
List of Tables
TABLE 1. FILGRASTIM & BIOSIMILARS MARKET SEGMENTATION & COVERAGE
TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2024
TABLE 3. GLOBAL FILGRASTIM & BIOSIMILARS MARKET SIZE, 2018-2024 (USD MILLION)
TABLE 4. GLOBAL FILGRASTIM & BIOSIMILARS MARKET SIZE, 2025-2030 (USD MILLION)
TABLE 5. GLOBAL FILGRASTIM & BIOSIMILARS MARKET SIZE, BY REGION, 2018-2024 (USD MILLION)
TABLE 6. GLOBAL FILGRASTIM & BIOSIMILARS MARKET SIZE, BY REGION, 2025-2030 (USD MILLION)
TABLE 7. GLOBAL FILGRASTIM & BIOSIMILARS MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
TABLE 8. GLOBAL FILGRASTIM & BIOSIMILARS MARKET SIZE, BY COUNTRY, 2025-2030 (USD MILLION)
TABLE 9. GLOBAL FILGRASTIM & BIOSIMILARS MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
TABLE 10. GLOBAL FILGRASTIM & BIOSIMILARS MARKET SIZE, BY PRODUCT TYPE, 2025-2030 (USD MILLION)
TABLE 11. GLOBAL FILGRASTIM & BIOSIMILARS MARKET SIZE, BY BIOSIMILAR FILGRASTIM, BY REGION, 2018-2024 (USD MILLION)
TABLE 12. GLOBAL FILGRASTIM & BIOSIMILARS MARKET SIZE, BY BIOSIMILAR FILGRASTIM, BY REGION, 2025-2030 (USD MILLION)
TABLE 13. GLOBAL FILGRASTIM & BIOSIMILARS MARKET SIZE, BY ACCOFIL, BY REGION, 2018-2024 (USD MILLION)
TABLE 14. GLOBAL FILGRASTIM & BIOSIMILARS MARKET SIZE, BY ACCOFIL, BY REGION, 2025-2030 (USD MILLION)
TABLE 15. GLOBAL FILGRASTIM & BIOSIMILARS MARKET SIZE, BY NIVESTIM, BY REGION, 2018-2024 (USD MILLION)
TABLE 16. GLOBAL FILGRASTIM & BIOSIMILARS MARKET SIZE, BY NIVESTIM, BY REGION, 2025-2030 (USD MILLION)
TABLE 17. GLOBAL FILGRASTIM & BIOSIMILARS MARKET SIZE, BY ZARXIO, BY REGION, 2018-2024 (USD MILLION)
TABLE 18. GLOBAL FILGRASTIM & BIOSIMILARS MARKET SIZE, BY ZARXIO, BY REGION, 2025-2030 (USD MILLION)
TABLE 19. GLOBAL FILGRASTIM & BIOSIMILARS MARKET SIZE, BY BIOSIMILAR FILGRASTIM, 2018-2024 (USD MILLION)
TABLE 20. GLOBAL FILGRASTIM & BIOSIMILARS MARKET SIZE, BY BIOSIMILAR FILGRASTIM, 2025-2030 (USD MILLION)
TABLE 21. GLOBAL FILGRASTIM & BIOSIMILARS MARKET SIZE, BY ORIGINATOR FILGRASTIM, BY REGION, 2018-2024 (USD MILLION)
TABLE 22. GLOBAL FILGRASTIM & BIOSIMILARS MARKET SIZE, BY ORIGINATOR FILGRASTIM, BY REGION, 2025-2030 (USD MILLION)
TABLE 23. GLOBAL FILGRASTIM & BIOSIMILARS MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
TABLE 24. GLOBAL FILGRASTIM & BIOSIMILARS MARKET SIZE, BY APPLICATION, 2025-2030 (USD MILLION)
TABLE 25. GLOBAL FILGRASTIM & BIOSIMILARS MARKET SIZE, BY CHEMOTHERAPY INDUCED NEUTROPENIA, BY REGION, 2018-2024 (USD MILLION)
TABLE 26. GLOBAL FILGRASTIM & BIOSIMILARS MARKET SIZE, BY CHEMOTHERAPY INDUCED NEUTROPENIA, BY REGION, 2025-2030 (USD MILLION)
TABLE 27. GLOBAL FILGRASTIM & BIOSIMILARS MARKET SIZE, BY HEMATOLOGIC MALIGNANCY TREATMENT, BY REGION, 2018-2024 (USD MILLION)
TABLE 28. GLOBAL FILGRASTIM & BIOSIMILARS MARKET SIZE, BY HEMATOLOGIC MALIGNANCY TREATMENT, BY REGION, 2025-2030 (USD MILLION)
TABLE 29. GLOBAL FILGRASTIM & BIOSIMILARS MARKET SIZE, BY SOLID TUMOR TREATMENT, BY REGION, 2018-2024 (USD MILLION)
TABLE 30. GLOBAL FILGRASTIM & BIOSIMILARS MARKET SIZE, BY SOLID TUMOR TREATMENT, BY REGION, 2025-2030 (USD MILLION)
TABLE 31. GLOBAL FILGRASTIM & BIOSIMILARS MARKET SIZE, BY CHEMOTHERAPY INDUCED NEUTROPENIA, 2018-2024 (USD MILLION)
TABLE 32. GLOBAL FILGRASTIM & BIOSIMILARS MARKET SIZE, BY CHEMOTHERAPY INDUCED NEUTROPENIA, 2025-2030 (USD MILLION)
TABLE 33. GLOBAL FILGRASTIM & BIOSIMILARS MARKET SIZE, BY SEVERE CHRONIC NEUTROPENIA, BY REGION, 2018-2024 (USD MILLION)
TABLE 34. GLOBAL FILGRASTIM & BIOSIMILARS MARKET SIZE, BY SEVERE CHRONIC NEUTROPENIA, BY REGION, 2025-2030 (USD MILLION)
TABLE 35. GLOBAL FILGRASTIM & BIOSIMILARS MARKET SIZE, BY STEM CELL MOBILIZATION, BY REGION, 2018-2024 (USD MILLION)
TABLE 36. GLOBAL FILGRASTIM & BIOSIMILARS MARKET SIZE, BY STEM CELL MOBILIZATION, BY REGION, 2025-2030 (USD MILLION)
TABLE 37. GLOBAL FILGRASTIM & BIOSIMILARS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 38. GLOBAL FILGRASTIM & BIOSIMILARS MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 39. GLOBAL FILGRASTIM & BIOSIMILARS MARKET SIZE, BY HOMECARE, BY REGION, 2018-2024 (USD MILLION)
TABLE 40. GLOBAL FILGRASTIM & BIOSIMILARS MARKET SIZE, BY HOMECARE, BY REGION, 2025-2030 (USD MILLION)
TABLE 41. GLOBAL FILGRASTIM & BIOSIMILARS MARKET SIZE, BY HOSPITAL, BY REGION, 2018-2024 (USD MILLION)
TABLE 42. GLOBAL FILGRASTIM & BIOSIMILARS MARKET SIZE, BY HOSPITAL, BY REGION, 2025-2030 (USD MILLION)
TABLE 43. GLOBAL FILGRASTIM & BIOSIMILARS MARKET SIZE, BY SPECIALTY CLINIC, BY REGION, 2018-2024 (USD MILLION)
TABLE 44. GLOBAL FILGRASTIM & BIOSIMILARS MARKET SIZE, BY SPECIALTY CLINIC, BY REGION, 2025-2030 (USD MILLION)
TABLE 45. GLOBAL FILGRASTIM & BIOSIMILARS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 46. GLOBAL FILGRASTIM & BIOSIMILARS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 47. GLOBAL FILGRASTIM & BIOSIMILARS MARKET SIZE, BY HOSPITAL PHARMACY, BY REGION, 2018-2024 (USD MILLION)
TABLE 48. GLOBAL FILGRASTIM & BIOSIMILARS MARKET SIZE, BY HOSPITAL PHARMACY, BY REGION, 2025-2030 (USD MILLION)
TABLE 49. GLOBAL FILGRASTIM & BIOSIMILARS MARKET SIZE, BY ONLINE PHARMACY, BY REGION, 2018-2024 (USD MILLION)
TABLE 50. GLOBAL FILGRASTIM & BIOSIMILARS MARKET SIZE, BY ONLINE PHARMACY, BY REGION, 2025-2030 (USD MILLION)
TABLE 51. GLOBAL FILGRASTIM & BIOSIMILARS MARKET SIZE, BY RETAIL PHARMACY, BY REGION, 2018-2024 (USD MILLION)
TABLE 52. GLOBAL FILGRASTIM & BIOSIMILARS MARKET SIZE, BY RETAIL PHARMACY, BY REGION, 2025-2030 (USD MILLION)
TABLE 53. GLOBAL FILGRASTIM & BIOSIMILARS MARKET SIZE, BY DOSAGE FORM, 2018-2024 (USD MILLION)
TABLE 54. GLOBAL FILGRASTIM & BIOSIMILARS MARKET SIZE, BY DOSAGE FORM, 2025-2030 (USD MILLION)
TABLE 55. GLOBAL FILGRASTIM & BIOSIMILARS MARKET SIZE, BY PREFILLED SYRINGE, BY REGION, 2018-2024 (USD MILLION)
TABLE 56. GLOBAL FILGRASTIM & BIOSIMILARS MARKET SIZE, BY PREFILLED SYRINGE, BY REGION, 2025-2030 (USD MILLION)
TABLE 57. GLOBAL FILGRASTIM & BIOSIMILARS MARKET SIZE, BY VIAL, BY REGION, 2018-2024 (USD MILLION)
TABLE 58. GLOBAL FILGRASTIM & BIOSIMILARS MARKET SIZE, BY VIAL, BY REGION, 2025-2030 (USD MILLION)
TABLE 59. GLOBAL FILGRASTIM & BIOSIMILARS MARKET SIZE, BY STRENGTH, 2018-2024 (USD MILLION)
TABLE 60. GLOBAL FILGRASTIM & BIOSIMILARS MARKET SIZE, BY STRENGTH, 2025-2030 (USD MILLION)
TABLE 61. GLOBAL FILGRASTIM & BIOSIMILARS MARKET SIZE, BY 300 MICROGRAM, BY REGION, 2018-2024 (USD MILLION)
TABLE 62. GLOBAL FILGRASTIM & BIOSIMILARS MARKET SIZE, BY 300 MICROGRAM, BY REGION, 2025-2030 (USD MILLION)
TABLE 63. GLOBAL FILGRASTIM & BIOSIMILARS MARKET SIZE, BY 480 MICROGRAM, BY REGION, 2018-2024 (USD MILLION)
TABLE 64. GLOBAL FILGRASTIM & BIOSIMILARS MARKET SIZE, BY 480 MICROGRAM, BY REGION, 2025-2030 (USD MILLION)
TABLE 65. AMERICAS FILGRASTIM & BIOSIMILARS MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
TABLE 66. AMERICAS FILGRASTIM & BIOSIMILARS MARKET SIZE, BY PRODUCT TYPE, 2025-2030 (USD MILLION)
TABLE 67. AMERICAS FILGRASTIM & BIOSIMILARS MARKET SIZE, BY BIOSIMILAR FILGRASTIM, 2018-2024 (USD MILLION)
TABLE 68. AMERICAS FILGRASTIM & BIOSIMILARS MARKET SIZE, BY BIOSIMILAR FILGRASTIM, 2025-2030 (USD MILLION)
TABLE 69. AMERICAS FILGRASTIM & BIOSIMILARS MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
TABLE 70. AMERICAS FILGRASTIM & BIOSIMILARS MARKET SIZE, BY APPLICATION, 2025-2030 (USD MILLION)
TABLE 71. AMERICAS FILGRASTIM & BIOSIMILARS MARKET SIZE, BY CHEMOTHERAPY INDUCED NEUTROPENIA, 2018-2024 (USD MILLION)
TABLE 72. AMERICAS FILGRASTIM & BIOSIMILARS MARKET SIZE, BY CHEMOTHERAPY INDUCED NEUTROPENIA, 2025-2030 (USD MILLION)
TABLE 73. AMERICAS FILGRASTIM & BIOSIMILARS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 74. AMERICAS FILGRASTIM & BIOSIMILARS MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 75. AMERICAS FILGRASTIM & BIOSIMILARS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 76. AMERICAS FILGRASTIM & BIOSIMILARS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 77. AMERICAS FILGRASTIM & BIOSIMILARS MARKET SIZE, BY DOSAGE FORM, 2018-2024 (USD MILLION)
TABLE 78. AMERICAS FILGRASTIM & BIOSIMILARS MARKET SIZE, BY DOSAGE FORM, 2025-2030 (USD MILLION)
TABLE 79. AMERICAS FILGRASTIM & BIOSIMILARS MARKET SIZE, BY STRENGTH, 2018-2024 (USD MILLION)
TABLE 80. AMERICAS FILGRASTIM & BIOSIMILARS MARKET SIZE, BY STRENGTH, 2025-2030 (USD MILLION)
TABLE 81. AMERICAS FILGRASTIM & BIOSIMILARS MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
TABLE 82. AMERICAS FILGRASTIM & BIOSIMILARS MARKET SIZE, BY COUNTRY, 2025-2030 (USD MILLION)
TABLE 83. UNITED STATES FILGRASTIM & BIOSIMILARS MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
TABLE 84. UNITED STATES FILGRASTIM & BIOSIMILARS MARKET SIZE, BY PRODUCT TYPE, 2025-2030 (USD MILLION)
TABLE 85. UNITED STATES FILGRASTIM & BIOSIMILARS MARKET SIZE, BY BIOSIMILAR FILGRASTIM, 2018-2024 (USD MILLION)
TABLE 86. UNITED STATES FILGRASTIM & BIOSIMILARS MARKET SIZE, BY BIOSIMILAR FILGRASTIM, 2025-2030 (USD MILLION)
TABLE 87. UNITED STATES FILGRASTIM & BIOSIMILARS MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
TABLE 88. UNITED STATES FILGRASTIM & BIOSIMILARS MARKET SIZE, BY APPLICATION, 2025-2030 (USD MILLION)
TABLE 89. UNITED STATES FILGRASTIM & BIOSIMILARS MARKET SIZE, BY CHEMOTHERAPY INDUCED NEUTROPENIA, 2018-2024 (USD MILLION)
TABLE 90. UNITED STATES FILGRASTIM & BIOSIMILARS MARKET SIZE, BY CHEMOTHERAPY INDUCED NEUTROPENIA, 2025-2030 (USD MILLION)
TABLE 91. UNITED STATES FILGRASTIM & BIOSIMILARS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 92. UNITED STATES FILGRASTIM & BIOSIMILARS MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 93. UNITED STATES FILGRASTIM & BIOSIMILARS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 94. UNITED STATES FILGRASTIM & BIOSIMILARS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 95. UNITED STATES FILGRASTIM & BIOSIMILARS MARKET SIZE, BY DOSAGE FORM, 2018-2024 (USD MILLION)
TABLE 96. UNITED STATES FILGRASTIM & BIOSIMILARS MARKET SIZE, BY DOSAGE FORM, 2025-2030 (USD MILLION)
TABLE 97. UNITED STATES FILGRASTIM & BIOSIMILARS MARKET SIZE, BY STRENGTH, 2018-2024 (USD MILLION)
TABLE 98. UNITED STATES FILGRASTIM & BIOSIMILARS MARKET SIZE, BY STRENGTH, 2025-2030 (USD MILLION)
TABLE 99. UNITED STATES FILGRASTIM & BIOSIMILARS MARKET SIZE, BY STATE, 2018-2024 (USD MILLION)
TABLE 100. UNITED STATES FILGRASTIM & BIOSIMILARS MARKET SIZE, BY STATE, 2025-2030 (USD MILLION)
TABLE 101. CANADA FILGRASTIM & BIOSIMILARS MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
TABLE 102. CANADA FILGRASTIM & BIOSIMILARS MARKET SIZE, BY PRODUCT TYPE, 2025-2030 (USD MILLION)
TABLE 103. CANADA FILGRASTIM & BIOSIMILARS MARKET SIZE, BY BIOSIMILAR FILGRASTIM, 2018-2024 (USD MILLION)
TABLE 104. CANADA FILGRASTIM & BIOSIMILARS MARKET SIZE, BY BIOSIMILAR FILGRASTIM, 2025-2030 (USD MILLION)
TABLE 105. CANADA FILGRASTIM & BIOSIMILARS MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
TABLE 106. CANADA FILGRASTIM & BIOSIMILARS MARKET SIZE, BY APPLICATION, 2025-2030 (USD MILLION)
TABLE 107. CANADA FILGRASTIM & BIOSIMILARS MARKET SIZE, BY CHEMOTHERAPY INDUCED NEUTROPENIA, 2018-2024 (USD MILLION)
TABLE 108. CANADA FILGRASTIM & BIOSIMILARS MARKET SIZE, BY CHEMOTHERAPY INDUCED NEUTROPENIA, 2025-2030 (USD MILLION)
TABLE 109. CANADA FILGRASTIM & BIOSIMILARS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 110. CANADA FILGRASTIM & BIOSIMILARS MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 111. CANADA FILGRASTIM & BIOSIMILARS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 112. CANADA FILGRASTIM & BIOSIMILARS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 113. CANADA FILGRASTIM & BIOSIMILARS MARKET SIZE, BY DOSAGE FORM, 2018-2024 (USD MILLION)
TABLE 114. CANADA FILGRASTIM & BIOSIMILARS MARKET SIZE, BY DOSAGE FORM, 2025-2030 (USD MILLION)
TABLE 115. CANADA FILGRASTIM & BIOSIMILARS MARKET SIZE, BY STRENGTH, 2018-2024 (USD MILLION)
TABLE 116. CANADA FILGRASTIM & BIOSIMILARS MARKET SIZE, BY STRENGTH, 2025-2030 (USD MILLION)
TABLE 117. MEXICO FILGRASTIM & BIOSIMILARS MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
TABLE 118. MEXICO FILGRASTIM & BIOSIMILARS MARKET SIZE, BY PRODUCT TYPE, 2025-2030 (USD MILLION)
TABLE 119. MEXICO FILGRASTIM & BIOSIMILARS MARKET SIZE, BY BIOSIMILAR FILGRASTIM, 2018-2024 (USD MILLION)
TABLE 120. MEXICO FILGRASTIM & BIOSIMILARS MARKET SIZE, BY BIOSIMILAR FILGRASTIM, 2025-2030 (USD MILLION)
TABLE 121. MEXICO FILGRASTIM & BIOSIMILARS MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
TABLE 122. MEXICO FILGRASTIM & BIOSIMILARS MARKET SIZE, BY APPLICATION, 2025-2030 (USD MILLION)
TABLE 123. MEXICO FILGRASTIM & BIOSIMILARS MARKET SIZE, BY CHEMOTHERAPY INDUCED NEUTROPENIA, 2018-2024 (USD MILLION)
TABLE 124. MEXICO FILGRASTIM & BIOSIMILARS MARKET SIZE, BY CHEMOTHERAPY INDUCED NEUTROPENIA, 2025-2030 (USD MILLION)
TABLE 125. MEXICO FILGRASTIM & BIOSIMILARS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 126. MEXICO FILGRASTIM & BIOSIMILARS MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 127. MEXICO FILGRASTIM & BIOSIMILARS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 128. MEXICO FILGRASTIM & BIOSIMILARS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 129. MEXICO FILGRASTIM & BIOSIMILARS MARKET SIZE, BY DOSAGE FORM, 2018-2024 (USD MILLION)
TABLE 130. MEXICO FILGRASTIM & BIOSIMILARS MARKET SIZE, BY DOSAGE FORM, 2025-2030 (USD MILLION)
TABLE 131. MEXICO FILGRASTIM & BIOSIMILARS MARKET SIZE, BY STRENGTH, 2018-2024 (USD MILLION)
TABLE 132. MEXICO FILGRASTIM & BIOSIMILARS MARKET SIZE, BY STRENGTH, 2025-2030 (USD MILLION)
TABLE 133. BRAZIL FILGRASTIM & BIOSIMILARS MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
TABLE 134. BRAZIL FILGRASTIM & BIOSIMILARS MARKET SIZE, BY PRODUCT TYPE, 2025-2030 (USD MILLION)
TABLE 135. BRAZIL FILGRASTIM & BIOSIMILARS MARKET SIZE, BY BIOSIMILAR FILGRASTIM, 2018-2024 (USD MILLION)
TABLE 136. BRAZIL FILGRASTIM & BIOSIMILARS MARKET SIZE, BY BIOSIMILAR FILGRASTIM, 2025-2030 (USD MILLION)
TABLE 137. BRAZIL FILGRASTIM & BIOSIMILARS MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
TABLE 138. BRAZIL FILGRASTIM & BIOSIMILARS MARKET SIZE, BY APPLICATION, 2025-2030 (USD MILLION)
TABLE 139. BRAZIL FILGRASTIM & BIOSIMILARS MARKET SIZE, BY CHEMOTHERAPY INDUCED NEUTROPENIA, 2018-2024 (USD MILLION)
TABLE 140. BRAZIL FILGRASTIM & BIOSIMILARS MARKET SIZE, BY CHEMOTHERAPY INDUCED NEUTROPENIA, 2025-2030 (USD MILLION)
TABLE 141. BRAZIL FILGRASTIM & BIOSIMILARS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 142. BRAZIL FILGRASTIM & BIOSIMILARS MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 143. BRAZIL FILGRASTIM & BIOSIMILARS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 144. BRAZIL FILGRASTIM & BIOSIMILARS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 145. BRAZIL FILGRASTIM & BIOSIMILARS MARKET SIZE, BY DOSAGE FORM, 2018-2024 (USD MILLION)
TABLE 146. BRAZIL FILGRASTIM & BIOSIMILARS MARKET SIZE, BY DOSAGE FORM, 2025-2030 (USD MILLION)
TABLE 147. BRAZIL FILGRASTIM & BIOSIMILARS MARKET SIZE, BY STRENGTH, 2018-2024 (USD MILLION)
TABLE 148. BRAZIL FILGRASTIM & BIOSIMILARS MARKET SIZE, BY STRENGTH, 2025-2030 (USD MILLION)
TABLE 149. ARGENTINA FILGRASTIM & BIOSIMILARS MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
TABLE 150. ARGENTINA FILGRASTIM & BIOSIMILARS MARKET SIZE, BY PRODUCT TYPE, 2025-2030 (USD MILLION)
TABLE 151. ARGENTINA FILGRASTIM & BIOSIMILARS MARKET SIZE, BY BIOSIMILAR FILGRASTIM, 2018-2024 (USD MILLION)
TABLE 152. ARGENTINA FILGRASTIM & BIOSIMILARS MARKET SIZE, BY BIOSIMILAR FILGRASTIM, 2025-2030 (USD MILLION)
TABLE 153. ARGENTINA FILGRASTIM & BIOSIMILARS MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
TABLE 154. ARGENTINA FILGRASTIM & BIOSIMILARS MARKET SIZE, BY APPLICATION, 2025-2030 (USD MILLION)
TABLE 155. ARGENTINA FILGRASTIM & BIOSIMILARS MARKET SIZE, BY CHEMOTHERAPY INDUCED NEUTROPENIA, 2018-2024 (USD MILLION)
TABLE 156. ARGENTINA FILGRASTIM & BIOSIMILARS MARKET SIZE, BY CHEMOTHERAPY INDUCED NEUTROPENIA, 2025-2030 (USD MILLION)
TABLE 157. ARGENTINA FILGRASTIM & BIOSIMILARS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 158. ARGENTINA FILGRASTIM & BIOSIMILARS MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 159. ARGENTINA FILGRASTIM & BIOSIMILARS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 160. ARGENTINA FILGRASTIM & BIOSIMILARS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 161. ARGENTINA FILGRASTIM & BIOSIMILARS MARKET SIZE, BY DOSAGE FORM, 2018-2024 (USD MILLION)
TABLE 162. ARGENTINA FILGRASTIM & BIOSIMILARS MARKET SIZE, BY DOSAGE FORM, 2025-2030 (USD MILLION)
TABLE 163. ARGENTINA FILGRASTIM & BIOSIMILARS MARKET SIZE, BY STRENGTH, 2018-2024 (USD MILLION)
TABLE 164. ARGENTINA FILGRASTIM & BIOSIMILARS MARKET SIZE, BY STRENGTH, 2025-2030 (USD MILLION)
TABLE 165. EUROPE, MIDDLE EAST & AFRICA FILGRASTIM & BIOSIMILARS MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
TABLE 166. EUROPE, MIDDLE EAST & AFRICA FILGRASTIM & BIOSIMILARS MARKET SIZE, BY PRODUCT TYPE, 2025-2030 (USD MILLION)
TABLE 167. EUROPE, MIDDLE EAST & AFRICA FILGRASTIM & BIOSIMILARS MARKET SIZE, BY BIOSIMILAR FILGRASTIM, 2018-2024 (USD MILLION)
TABLE 168. EUROPE, MIDDLE EAST & AFRICA FILGRASTIM & BIOSIMILARS MARKET SIZE, BY BIOSIMILAR FILGRASTIM, 2025-2030 (USD MILLION)
TABLE 169. EUROPE, MIDDLE EAST & AFRICA FILGRASTIM & BIOSIMILARS MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
TABLE 170. EUROPE, MIDDLE EAST & AFRICA FILGRASTIM & BIOSIMILARS MARKET SIZE, BY APPLICATION, 2025-2030 (USD MILLION)
TABLE 171. EUROPE, MIDDLE EAST & AFRICA FILGRASTIM & BIOSIMILARS MARKET SIZE, BY CHEMOTHERAPY INDUCED NEUTROPENIA, 2018-2024 (USD MILLION)
TABLE 172. EUROPE, MIDDLE EAST & AFRICA FILGRASTIM & BIOSIMILARS MARKET SIZE, BY CHEMOTHERAPY INDUCED NEUTROPENIA, 2025-2030 (USD MILLION)
TABLE 173. EUROPE, MIDDLE EAST & AFRICA FILGRASTIM & BIOSIMILARS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 174. EUROPE, MIDDLE EAST & AFRICA FILGRASTIM & BIOSIMILARS MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 175. EUROPE, MIDDLE EAST & AFRICA FILGRASTIM & BIOSIMILARS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 176. EUROPE, MIDDLE EAST & AFRICA FILGRASTIM & BIOSIMILARS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 177. EUROPE, MIDDLE EAST & AFRICA FILGRASTIM & BIOSIMILARS MARKET SIZE, BY DOSAGE FORM, 2018-2024 (USD MILLION)
TABLE 178. EUROPE, MIDDLE EAST & AFRICA FILGRASTIM & BIOSIMILARS MARKET SIZE, BY DOSAGE FORM, 2025-2030 (USD MILLION)
TABLE 179. EUROPE, MIDDLE EAST & AFRICA FILGRASTIM & BIOSIMILARS MARKET SIZE, BY STRENGTH, 2018-2024 (USD MILLION)
TABLE 180. EUROPE, MIDDLE EAST & AFRICA FILGRASTIM & BIOSIMILARS MARKET SIZE, BY STRENGTH, 2025-2030 (USD MILLION)
TABLE 181. EUROPE, MIDDLE EAST & AFRICA FILGRASTIM & BIOSIMILARS MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
TABLE 182. EUROPE, MIDDLE EAST & AFRICA FILGRASTIM & BIOSIMILARS MARKET SIZE, BY COUNTRY, 2025-2030 (USD MILLION)
TABLE 183. UNITED KINGDOM FILGRASTIM & BIOSIMILARS MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
TABLE 184. UNITED KINGDOM FILGRASTIM & BIOSIMILARS MARKET SIZE, BY PRODUCT TYPE, 2025-2030 (USD MILLION)
TABLE 185. UNITED KINGDOM FILGRASTIM & BIOSIMILARS MARKET SIZE, BY BIOSIMILAR FILGRASTIM, 2018-2024 (USD MILLION)
TABLE 186. UNITED KINGDOM FILGRASTIM & BIOSIMILARS MARKET SIZE, BY BIOSIMILAR FILGRASTIM, 2025-2030 (USD MILLION)
TABLE 187. UNITED KINGDOM FILGRASTIM & BIOSIMILARS MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
TABLE 188. UNITED KINGDOM FILGRASTIM & BIOSIMILARS MARKET SIZE, BY APPLICATION, 2025-2030 (USD MILLION)
TABLE 189. UNITED KINGDOM FILGRASTIM & BIOSIMILARS MARKET SIZE, BY CHEMOTHERAPY INDUCED NEUTROPENIA, 2018-2024 (USD MILLION)
TABLE 190. UNITED KINGDOM FILGRASTIM & BIOSIMILARS MARKET SIZE, BY CHEMOTHERAPY INDUCED NEUTROPENIA, 2025-2030 (USD MILLION)
TABLE 191. UNITED KINGDOM FILGRASTIM & BIOSIMILARS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 192. UNITED KINGDOM FILGRASTIM & BIOSIMILARS MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 193. UNITED KINGDOM FILGRASTIM & BIOSIMILARS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 194. UNITED KINGDOM FILGRASTIM & BIOSIMILARS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 195. UNITED KINGDOM FILGRASTIM & BIOSIMILARS MARKET SIZE, BY DOSAGE FORM, 2018-2024 (USD MILLION)
TABLE 196. UNITED KINGDOM FILGRASTIM & BIOSIMILARS MARKET SIZE, BY DOSAGE FORM, 2025-2030 (USD MILLION)
TABLE 197. UNITED KINGDOM FILGRASTIM & BIOSIMILARS MARKET SIZE, BY STRENGTH, 2018-2024 (USD MILLION)
TABLE 198. UNITED KINGDOM FILGRASTIM & BIOSIMILARS MARKET SIZE, BY STRENGTH, 2025-2030 (USD MILLION)
TABLE 199. GERMANY FILGRASTIM & BIOSIMILARS MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
TABLE 200. GERMANY FILGRASTIM & BIOSIMILARS MARKET SIZE, BY PRODUCT TYPE, 2025-2030 (USD MILLION)
TABLE 201. GERMANY FILGRASTIM & BIOSIMILARS MARKET SIZE, BY BIOSIMILAR FILGRASTIM, 2018-2024 (USD MILLION)
TABLE 202. GERMANY FILGRASTIM & BIOSIMILARS MARKET SIZE, BY BIOSIMILAR FILGRASTIM, 2025-2030 (USD MILLION)
TABLE 203. GERMANY FILGRASTIM & BIOSIMILARS MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
TABLE 204. GERMANY FILGRASTIM & BIOSIMILARS MARKET SIZE, BY APPLICATION, 2025-2030 (USD MILLION)
TABLE 205. GERMANY FILGRASTIM & BIOSIMILARS MARKET SIZE, BY CHEMOTHERAPY INDUCED NEUTROPENIA, 2018-2024 (USD MILLION)
TABLE 206. GERMANY FILGRASTIM & BIOSIMILARS MARKET SIZE, BY CHEMOTHERAPY INDUCED NEUTROPENIA, 2025-2030 (USD MILLION)
TABLE 207. GERMANY FILGRASTIM & BIOSIMILARS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 208. GERMANY FILGRASTIM & BIOSIMILARS MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 209. GERMANY FILGRASTIM & BIOSIMILARS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 210. GERMANY FILGRASTIM & BIOSIMILARS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 211. GERMANY FILGRASTIM & BIOSIMILARS MARKET SIZE, BY DOSAGE FORM, 2018-2024 (USD MILLION)
TABLE 212. GERMANY FILGRASTIM & BIOSIMILARS MARKET SIZE, BY DOSAGE FORM, 2025-2030 (USD MILLION)
TABLE 213. GERMANY FILGRASTIM & BIOSIMILARS MARKET SIZE, BY STRENGTH, 2018-2024 (USD MILLION)
TABLE 214. GERMANY FILGRASTIM & BIOSIMILARS MARKET SIZE, BY STRENGTH, 2025-2030 (USD MILLION)
TABLE 215. FRANCE FILGRASTIM & BIOSIMILARS MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
TABLE 216. FRANCE FILGRASTIM & BIOSIMILARS MARKET SIZE, BY PRODUCT TYPE, 2025-2030 (USD MILLION)
TABLE 217. FRANCE FILGRASTIM & BIOSIMILARS MARKET SIZE, BY BIOSIMILAR FILGRASTIM, 2018-2024 (USD MILLION)
TABLE 218. FRANCE FILGRASTIM & BIOSIMILARS MARKET SIZE, BY BIOSIMILAR FILGRASTIM, 2025-2030 (USD MILLION)
TABLE 219. FRANCE FILGRASTIM & BIOSIMILARS MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
TABLE 220. FRANCE FILGRASTIM & BIOSIMILARS MARKET SIZE, BY APPLICATION, 2025-2030 (USD MILLION)
TABLE 221. FRANCE FILGRASTIM & BIOSIMILARS MARKET SIZE, BY CHEMOTHERAPY INDUCED NEUTROPENIA, 2018-2024 (USD MILLION)
TABLE 222. FRANCE FILGRASTIM & BIOSIMILARS MARKET SIZE, BY CHEMOTHERAPY INDUCED NEUTROPENIA, 2025-2030 (USD MILLION)
TABLE 223. FRANCE FILGRASTIM & BIOSIMILARS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 224. FRANCE FILGRASTIM & BIOSIMILARS MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 225. FRANCE FILGRASTIM & BIOSIMILARS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 226. FRANCE FILGRASTIM & BIOSIMILARS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 227. FRANCE FILGRASTIM & BIOSIMILARS MARKET SIZE, BY DOSAGE FORM, 2018-2024 (USD MILLION)
TABLE 228. FRANCE FILGRASTIM & BIOSIMILARS MARKET SIZE, BY DOSAGE FORM, 2025-2030 (USD MILLION)
TABLE 229. FRANCE FILGRASTIM & BIOSIMILARS MARKET SIZE, BY STRENGTH, 2018-2024 (USD MILLION)
TABLE 230. FRANCE FILGRASTIM & BIOSIMILARS MARKET SIZE, BY STRENGTH, 2025-2030 (USD MILLION)
TABLE 231. RUSSIA FILGRASTIM & BIOSIMILARS MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
TABLE 232. RUSSIA FILGRASTIM & BIOSIMILARS MARKET SIZE, BY PRODUCT TYPE, 2025-2030 (USD MILLION)
TABLE 233. RUSSIA FILGRASTIM & BIOSIMILARS MARKET SIZE, BY BIOSIMILAR FILGRASTIM, 2018-2024 (USD MILLION)
TABLE 234. RUSSIA FILGRASTIM & BIOSIMILARS MARKET SIZE, BY BIOSIMILAR FILGRASTIM, 2025-2030 (USD MILLION)
TABLE 235. RUSSIA FILGRASTIM & BIOSIMILARS MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
TABLE 236. RUSSIA FILGRASTIM & BIOSIMILARS MARKET SIZE, BY APPLICATION, 2025-2030 (USD MILLION)
TABLE 237. RUSSIA FILGRASTIM & BIOSIMILARS MARKET SIZE, BY CHEMOTHERAPY INDUCED NEUTROPENIA, 2018-2024 (USD MILLION)
TABLE 238. RUSSIA FILGRASTIM & BIOSIMILARS MARKET SIZE, BY CHEMOTHERAPY INDUCED NEUTROPENIA, 2025-2030 (USD MILLION)
TABLE 239. RUSSIA FILGRASTIM & BIOSIMILARS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 240. RUSSIA FILGRASTIM & BIOSIMILARS MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 241. RUSSIA FILGRASTIM & BIOSIMILARS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 242. RUSSIA FILGRASTIM & BIOSIMILARS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 243. RUSSIA FILGRASTIM & BIOSIMILARS MARKET SIZE, BY DOSAGE FORM, 2018-2024 (USD MILLION)
TABLE 244. RUSSIA FILGRASTIM & BIOSIMILARS MARKET SIZE, BY DOSAGE FORM, 2025-2030 (USD MILLION)
TABLE 245. RUSSIA FILGRASTIM & BIOSIMILARS MARKET SIZE, BY STRENGTH, 2018-2024 (USD MILLION)
TABLE 246. RUSSIA FILGRASTIM & BIOSIMILARS MARKET SIZE, BY STRENGTH, 2025-2030 (USD MILLION)
TABLE 247. ITALY FILGRASTIM & BIOSIMILARS MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
TABLE 248. ITALY FILGRASTIM & BIOSIMILARS MARKET SIZE, BY PRODUCT TYPE, 2025-2030 (USD MILLION)
TABLE 249. ITALY FILGRASTIM & BIOSIMILARS MARKET SIZE, BY BIOSIMILAR FILGRASTIM, 2018-2024 (USD MILLION)
TABLE 250. ITALY FILGRASTIM & BIOSIMILARS MARKET SIZE, BY BIOSIMILAR FILGRASTIM, 2025-2030 (USD MILLION)
TABLE 251. ITALY FILGRASTIM & BIOSIMILARS MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
TABLE 252. ITALY FILGRASTIM & BIOSIMILARS MARKET SIZE, BY APPLICATION, 2025-2030 (USD MILLION)
TABLE 253. ITALY FILGRASTIM & BIOSIMILARS MARKET SIZE, BY CHEMOTHERAPY INDUCED NEUTROPENIA, 2018-2024 (USD MILLION)
TABLE 254. ITALY FILGRASTIM & BIOSIMILARS MARKET SIZE, BY CHEMOTHERAPY INDUCED NEUTROPENIA, 2025-2030 (USD MILLION)
TABLE 255. ITALY FILGRASTIM & BIOSIMILARS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 256. ITALY FILGRASTIM & BIOSIMILARS MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 257. ITALY FILGRASTIM & BIOSIMILARS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 258. ITALY FILGRASTIM & BIOSIMILARS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 259. ITALY FILGRASTIM & BIOSIMILARS MARKET SIZE, BY DOSAGE FORM, 2018-2024 (USD MILLION)
TABLE 260. ITALY FILGRASTIM & BIOSIMILARS MARKET SIZE, BY DOSAGE FORM, 2025-2030 (USD MILLION)
TABLE 261. ITALY FILGRASTIM & BIOSIMILARS MARKET SIZE, BY STRENGTH, 2018-2024 (USD MILLION)
TABLE 262. ITALY FILGRASTIM & BIOSIMILARS MARKET SIZE, BY STRENGTH, 2025-2030 (USD MILLION)
TABLE 263. SPAIN FILGRASTIM & BIOSIMILARS MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
TABLE 264. SPAIN FILGRASTIM & BIOSIMILARS MARKET SIZE, BY PRODUCT TYPE, 2025-2030 (USD MILLION)
TABLE 265. SPAIN FILGRASTIM & BIOSIMILARS MARKET SIZE, BY BIOSIMILAR FILGRASTIM, 2018-2024 (USD MILLION)
TABLE 266. SPAIN FILGRASTIM & BIOSIMILARS MARKET SIZE, BY BIOSIMILAR FILGRASTIM, 2025-2030 (USD MILLION)
TABLE 267. SPAIN FILGRASTIM & BIOSIMILARS MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
TABLE 268. SPAIN FILGRASTIM & BIOSIMILARS MARKET SIZE, BY APPLICATION, 2025-2030 (USD MILLION)
TABLE 269. SPAIN FILGRASTIM & BIOSIMILARS MARKET SIZE, BY CHEMOTHERAPY INDUCED NEUTROPENIA, 2018-2024 (USD MILLION)
TABLE 270. SPAIN FILGRASTIM & BIOSIMILARS MARKET SIZE, BY CHEMOTHERAPY INDUCED NEUTROPENIA, 2025-2030 (USD MILLION)
TABLE 271. SPAIN FILGRASTIM & BIOSIMILARS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 272. SPAIN FILGRASTIM & BIOSIMILARS MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 273. SPAIN FILGRASTIM & BIOSIMILARS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 274. SPAIN FILGRASTIM & BIOSIMILARS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 275. SPAIN FILGRASTIM & BIOSIMILARS MARKET SIZE, BY DOSAGE FORM, 2018-2024 (USD MILLION)
TABLE 276. SPAIN FILGRASTIM & BIOSIMILARS MARKET SIZE, BY DOSAGE FORM, 2025-2030 (USD MILLION)
TABLE 277. SPAIN FILGRASTIM & BIOSIMILARS MARKET SIZE, BY STRENGTH, 2018-2024 (USD MILLION)
TABLE 278. SPAIN FILGRASTIM & BIOSIMILARS MARKET SIZE, BY STRENGTH, 2025-2030 (USD MILLION)
TABLE 279. UNITED ARAB EMIRATES FILGRASTIM & BIOSIMILARS MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
TABLE 280. UNITED ARAB EMIRATES FILGRASTIM & BIOSIMILARS MARKET SIZE, BY PRODUCT TYPE, 2025-2030 (USD MILLION)
TABLE 281. UNITED ARAB EMIRATES FILGRASTIM & BIOSIMILARS MARKET SIZE, BY BIOSIMILAR FILGRASTIM, 2018-2024 (USD MILLION)
TABLE 282. UNITED ARAB EMIRATES FILGRASTIM & BIOSIMILARS MARKET SIZE, BY BIOSIMILAR FILGRASTIM, 2025-2030 (USD MILLION)
TABLE 283. UNITED ARAB EMIRATES FILGRASTIM & BIOSIMILARS MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
TABLE 284. UNITED ARAB EMIRATES FILGRASTIM & BIOSIMILARS MARKET SIZE, BY APPLICATION, 2025-2030 (USD MILLION)
TABLE 285. UNITED ARAB EMIRATES FILGRASTIM & BIOSIMILARS MARKET SIZE, BY CHEMOTHERAPY INDUCED NEUTROPENIA, 2018-2024 (USD MILLION)
TABLE 286. UNITED ARAB EMIRATES FILGRASTIM & BIOSIMILARS MARKET SIZE, BY CHEMOTHERAPY INDUCED NEUTROPENIA, 2025-2030 (USD MILLION)
TABLE 287. UNITED ARAB EMIRATES FILGRASTIM & BIOSIMILARS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 288. UNITED ARAB EMIRATES FILGRASTIM & BIOSIMILARS MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 289. UNITED ARAB EMIRATES FILGRASTIM & BIOSIMILARS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 290. UNITED ARAB EMIRATES FILGRASTIM & BIOSIMILARS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 291. UNITED ARAB EMIRATES FILGRASTIM & BIOSIMILARS MARKET SIZE, BY DOSAGE FORM, 2018-2024 (USD MILLION)
TABLE 292. UNITED ARAB EMIRATES FILGRASTIM & BIOSIMILARS MARKET SIZE, BY DOSAGE FORM, 2025-2030 (USD MILLION)
TABLE 293. UNITED ARAB EMIRATES FILGRASTIM & BIOSIMILARS MARKET SIZE, BY STRENGTH, 2018-2024 (USD MILLION)
TABLE 294. UNITED ARAB EMIRATES FILGRASTIM & BIOSIMILARS MARKET SIZE, BY STRENGTH, 2025-2030 (USD MILLION)
TABLE 295. SAUDI ARABIA FILGRASTIM & BIOSIMILARS MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
TABLE 296. SAUDI ARABIA FILGRASTIM & BIOSIMILARS MARKET SIZE, BY PRODUCT TYPE, 2025-2030 (USD MILLION)
TABLE 297. SAUDI ARABIA FILGRASTIM & BIOSIMILARS MARKET SIZE, BY BIOSIMILAR FILGRASTIM, 2018-2024 (USD MILLION)
TABLE 298. SAUDI ARABIA FILGRASTIM & BIOSIMILARS MARKET SIZE, BY BIOSIMILAR FILGRASTIM, 2025-2030 (USD MILLION)
TABLE 299. SAUDI ARABIA FILGRASTIM & BIOSIMILARS MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
TABLE 300. SAUDI ARABIA FILGRASTIM & BIOSIMILARS MARKET SIZE, BY APPLICATION, 2025-2030 (USD MILLION)
TABLE 301. SAUDI ARABIA FILGRASTIM & BIOSIMILARS MARKET SIZE, BY CHEMOTHERAPY INDUCED NEUTROPENIA, 2018-2024 (USD MILLION)
TABLE 302. SAUDI ARABIA FILGRASTIM & BIOSIMILARS MARKET SIZE, BY CHEMOTHERAPY INDUCED NEUTROPENIA, 2025-2030 (USD MILLION)
TABLE 303. SAUDI ARABIA FILGRASTIM & BIOSIMILARS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 304. SAUDI ARABIA FILGRASTIM & BIOSIMILARS MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 305. SAUDI ARABIA FILGRASTIM & BIOSIMILARS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 306. SAUDI ARABIA FILGRASTIM & BIOSIMILARS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 307. SAUDI ARABIA FILGRASTIM & BIOSIMILARS MARKET SIZE, BY DOSAGE FORM, 2018-2024 (USD MILLION)
TABLE 308. SAUDI ARABIA FILGRASTIM & BIOSIMILARS MARKET SIZE, BY DOSAGE FORM, 2025-2030 (USD MILLION)
TABLE 309. SAUDI ARABIA FILGRASTIM & BIOSIMILARS MARKET SIZE, BY STRENGTH, 2018-2024 (USD MILLION)
TABLE 310. SAUDI ARABIA FILGRASTIM & BIOSIMILARS MARKET SIZE, BY STRENGTH, 2025-2030 (USD MILLION)
TABLE 311. SOUTH AFRICA FILGRASTIM & BIOSIMILARS MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
TABLE 312. SOUTH AFRICA FILGRASTIM & BIOSIMILARS MARKET SIZE, BY PRODUCT TYPE, 2025-2030 (USD MILLION)
TABLE 313. SOUTH AFRICA FILGRASTIM & BIOSIMILARS MARKET SIZE, BY BIOSIMILAR FILGRASTIM, 2018-2024 (USD MILLION)
TABLE 314. SOUTH AFRICA FILGRASTIM & BIOSIMILARS MARKET SIZE, BY BIOSIMILAR FILGRASTIM, 2025-2030 (USD MILLION)
TABLE 315. SOUTH AFRICA FIL

Samples

Loading
LOADING...

Companies Mentioned

The companies profiled in this Filgrastim & Biosimilars market report include:
  • Amgen Inc.
  • Sandoz International GmbH
  • Teva Pharmaceutical Industries Ltd.
  • Pfizer Inc.
  • Viatris Inc.
  • Biocon Biologics Ltd.
  • Celltrion Inc.
  • Apotex Inc.
  • Intas Pharmaceuticals Ltd.
  • Fresenius Kabi AG

Related Topics

Related Reports

Filgrastim Biosimilars Market Report 2025 - Product Image

Filgrastim Biosimilars Market Report 2025

  • Report
  • 250 Pages
  • Global
From
Neupogen (filgrastim) Global Market Report 2025: Epidemiology, Pipeline Analysis, Market Insights & Forecasts - Product Image

Neupogen (filgrastim) Global Market Report 2025: Epidemiology, Pipeline Analysis, Market Insights & Forecasts

  • Report
  • 175 Pages
  • Global
From
Filgrastim Biosimilar Market Report: Trends, Forecast and Competitive Analysis to 2031 - Product Image

Filgrastim Biosimilar Market Report: Trends, Forecast and Competitive Analysis to 2031

  • Report
  • 150 Pages
  • Global
From
Biosimilar Market Report 2025-2033 - Product Image

Biosimilar Market Report 2025-2033

  • Report
  • 123 Pages
  • Global
From
Chemotherapy Induced Neutropenia Market - Global Forecast 2025-2030 - Product Image

Chemotherapy Induced Neutropenia Market - Global Forecast 2025-2030

  • Report
  • 190 Pages
  • Global
From
Copyright © 2002-2025 Research and Markets. All Rights Reserved.